Avalanche
Biotechnologies Inc. (Nasdaq: AAVL) widened second quarter losses and
announced that it will not initiate a Phase 2b clinical trial of AVA-101
in the second half of 2015. The stock price plunged $3.82 to close at $10.01.
Avalanche abandons Phase 2b plans
August 14, 2015 at 10:01 AM EDT
